Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Methylphenidate as Needed for Fatigue in Patients With Advanced Cancer. A Prospective, Double-Blind, and Placebo-Controlled Study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Causes of hospital admissions in Domus: a randomized controlled trial of specialized palliative cancer care at home

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Comparison of EORTC QLQ-C30 and PRO-CTCAE™ Questionnaires on Six Symptom Items

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Stability and Priority of Symptoms and Symptom Clusters Among Allogeneic HSCT Patients Within a 5-Year Longitudinal Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Characteristics of patients reporting symptoms by open-ended questions in specialist palliative care

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Determining minimal important change for the thyroid-related quality of life questionnaire ThyPRO

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

CONTEXT: Cancer-related fatigue is a highly prevalent symptom with a strong negative impact on patients' daily life.

OBJECTIVES: To evaluate the efficacy of methylphenidate as needed for the management of fatigue in patients with advanced cancer.

METHODS: A prospective, controlled, double-blind, and paired design, where the patient was her and/or his own control. Patients with advanced cancer with a tiredness score of ≥50 on a 0-100 visual analogue scale (VAS) were included. Patients were given 10 placebo and 10 methylphenidate tablets numbered 1-20 packed in blocks of four with two active and two placebo tablets (randomly arranged). Patients taking minimum three tablets were regarded evaluable. Primary effect parameters were mean differences in VAS for tiredness after two and five hours. With 28 evaluable patients, the study had a power of 0.90 to detect a mean difference of 15 between active and placebo.

RESULTS: Thirty-eight patients were enrolled to get 28 evaluable patients. Mean tiredness score before taking the tablets was 75 for placebo and 72 for methylphenidate on VAS (0-100). Mean changes (decrease) for methylphenidate after two and five hours were 20 and 17, respectively, and eight and five for placebo. Comparing mean differences, a significant decrease for methylphenidate compared with placebo was observed after two hours (P = 0.004) and five hours (P = 0.001), respectively.

CONCLUSION: In this controlled and double-blind study in patients with advanced cancer, methylphenidate as needed was significantly more effective than placebo in relieving fatigue after two and five hours.

Original languageEnglish
JournalJournal of Pain and Symptom Management
Volume60
Issue number5
Pages (from-to)992-1002
Number of pages11
ISSN0885-3924
DOIs
Publication statusPublished - Nov 2020

ID: 61360827